Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus DROSPIRENONE.
Head-to-head clinical analysis: AMEN versus DROSPIRENONE.
AMEN vs DROSPIRENONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
3 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Category C
Category C
Progestin
Progestin